A critical factor for both the lowering in costs of development as well as costs of production for biologic therapies is to develop a cell line that grows faster and produces larger amounts of vaccines and drugs using low cost synthetically defined media.
Dyadic’s industrially proven C1 gene expression platform creates a stable cell line in a shortened timeline, reducing the time from gene fragment to stable cell line by 50% when compared to CHO cells. C1 stable cell lines can be developed in under three months versus six-plus months typically needed for CHO. Just as importantly, C1’s productivity is higher despite the much shorter time needed for production of biologics.
Please fill out this form to download the white paper.